Categories Earnings, Retail

Levi Strauss’ Q3 earnings beat estimates; confirms FY19 outlook

Denim jeans maker Levi Strauss (NYSE: LEVI) reported third quarter 2019 financial results that surpassed the market’s estimates. In its second earnings report after becoming public in March 2019, Levi Strauss posted adjusted earnings of $0.31 per share on revenue of $1.45 billion. Analysts had projected the company to earn $0.28 per share on revenue of $1.44 billion.

The San Francisco, California-based company reaffirmed its fiscal year 2019 outlook. LEVI stock, which ended down 1.92% today at $19.39, was up about 1% in the after-market session immediately after the earnings announcement.

Levi Strauss' (LEVI) Q3 earnings beat estimates; confirms FY19 outlook

GAAP profit per share declined 3% year-over-year to $0.30, while revenue grew 4% on a reported basis and 5% on a constant currency basis.

“As for the fourth quarter, we again expect strong performance in international, direct-to-consumer, women’s and tops, and improved comparisons for U.S. wholesale,” said CEO Chip Bergh.

For the fiscal year 2019, Levi Strauss maintained its outlook. The company expects constant-currency revenue growth to be 5.5% to 6.0%. Capital expenditure for the full fiscal year is estimated to be between $190 million and $200 million. Levi Strauss expects to open nearly 100 new company-operated stores in 2019.

Read: Apparel retail stocks to watch in times of tariff war

Revenue in the Americas region fell 3% both on a reported basis and constant-currency basis due to a drop in the wholesale business. Europe and Asia regions had a reported revenue growth of 14% and 9%, respectively, benefitting from strong performance from direct-to-consumer and wholesale channels in the regions.

In August, shares of Levi Strauss traded below its IPO price of $17 and reached a low of $16.00.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top